



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/966,036	09/28/2001	Dorrie M. Happ	50623.132	4580

7590 01/11/2006

Squire, Sanders & Dempsey L.L.P.
Suite 300
One Maritime Plaza
San Francisco, CA 94111

EXAMINER

FUBARA, BLESSING M

ART UNIT

PAPER NUMBER

1618

DATE MAILED: 01/11/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No. 09/966,036	Applicant(s) HAPP, DORRIE M.	
	Examiner Blessing M. Fubara	Art Unit 1618	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 11 October 2005.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 2-5, 7-11, 14-17, 19, 21 and 23-48 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 2-5, 7-11, 14-17, 19, 21 and 23-48 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Examiner acknowledges receipt of statement of common ownership, claim amendments and remarks, all filed 10/11/05. Claims 2-5, 7-11, 14-17, 19, 21 and 23-48 are pending.

Statement of Common Ownership:

Applicant's statement of common ownership of US 6,656,506 with examined application and thus removes Wu et al. (US 6,656,506) as art.

Llanos was cited as art of interest and applicant has not commented on Llanos. Therefore a rejection is made below.

Claim Rejections - 35 USC § 103

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

1. The rejection of claims 2-5, 7-11, 14-17, 19, 21 and 23-48 under 35 U.S.C. 103(a) as being unpatentable over Wu et al. (US 6,656,506) is withdrawn in light of the statement of common ownership removing Wu as art.
2. Claims 2-5, 7-11, 14-17, 19, 21 and 23-48 are rejected under 35 U.S.C. 103(a) as being unpatentable over Llanos et al. (US 6,746,773).

Llanos discloses coating composition and method of coating medical composition with the coating composition where a first layer is top coated with a top coating layer; both coating layers contain polymer and drugs (abstract; column 2, lines 25-36; column 6, lines 19 to column 8 line 21; Examples 1-8). Paclitaxel, vincristine and actinomycin D are some of the drugs used in the coating composition (column 6, lines 52, 53 and 55). Llanos contemplates coating medical

Art Unit: 1618

device such as stent (see Figure 4). Paclitaxel, vincristine and actinomycin D are recited in claim 4 as light sensitive drugs.

Llanos does not disclose the ratio of the UV-protective compound to polymer in the topcoat. Regarding the thickness of the layer, it is not inventive to determine how thick the layer is without showing the criticality of the thickness. There is no demonstration in applicant's specification showing that certain amount of the light or UV-protective compound relative to certain amount of the polymer in the top-coating composition provides unusual results to the coated medical device. Therefore, it would have been obvious to one of ordinary skill in the art at the time the invention was made to coat a medical device with a coating composition that contains drug and polymer and to top-coat the initial-layers with a composition that contains drug, polymer and gold as disclosed in Llanos. One having ordinary skill in the art would have been motivated to use amounts of the light or UV-protecting and polymer in mass ratios appropriate to provide the desired effect.

3. The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. Shanton (US 5,776,619) discloses coating composition that contains polymer and UV-protective compounds (abstract and claims 1-29).


Any inquiry concerning this communication or earlier communications from the examiner should be directed to Blessing M. Fubara whose telephone number is (571) 272-0594. The examiner can normally be reached on 7 a.m. to 3:30 p.m. (Monday to Friday).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael G. Hartley can be reached on (571) 272-0616. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Art Unit: 1618

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Blessing Fubara
Patent Examiner
Tech. Center 1600

A handwritten signature in black ink, appearing to read 'mfubara', is written over the printed name 'Blessing Fubara'.